CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

Summary

This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study.

Timeline

Start

2021-12-15

Primary completion

2024-01-31

Completion

2024-12-31

Publications

• Sannar EM, Winter J, Franke RK, Werner E, Rochowiak R, Romani PW, Miller OS, Semmler N, Bainbridge JL, Natvig C, Mikulich-Gilbertson SK, Tartaglia NR. Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. Int J Clin Trials. 2025 Jan-Mar;12(1):29-37. doi: 10.18203/2349-3259.ijct20250131. Epub 2025 Jan 28.
• Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.

Drugs

Indications